title: Safety, humoral and cell-mediated immune responses to herpes zoster vaccine in subjects with diabetes mellitus.
abstract: OBJECTIVE
  To evaluate varicella zoster virus-specific cell-mediated immunity and humoral immunogenicity against the herpes zoster vaccine, which is licensed as the Live Varicella Vaccine (Oka Strain) in Japan, in elderly people with or without diabetes mellitus.
  
  
  METHODS
  A pilot study was conducted between May 2010 and November 2010 at Kitano Hospital, a general hospital in the city of Osaka in Japan. A varicella skin test, interferon-gamma enzyme-linked immunospot assay and immunoadherence hemagglutination tests were performed 0, 3, and 6 months after vaccination. Vaccine safety was also assessed using questionnaires for 42 days and development of zoster during the one-year observational period. We enrolled 10 healthy volunteers and 10 patients with diabetes mellitus aged 60-70 years.
  
  
  RESULTS
  The live herpes zoster vaccine boosted virus-specific, cell-mediated and humoral immunity between elderly people, with or without diabetes. Moreover, no systemic adverse reaction was found. None of the study participants developed herpes zoster.
  
  
  CONCLUSIONS
  The live herpes zoster vaccine was used safely. It effectively enhanced specific immunity to varicella zoster virus in older people with or without diabetes mellitus.
authors.affiliation: Department of Infectious Diseases, Kitano Hospital, The Tazuke Kofukai Medical Research Institute, 2-4-20 Ohgimachi, Kitaku, Osaka 530-8480, Japan. ahata@kitano-hp.or.jp
authors.forename: Atsuko
authors.initials: A
authors.lastname: Hata
authors.forename: Fukue
authors.initials: F
authors.lastname: Inoue
authors.forename: Midori
authors.initials: M
authors.lastname: Yamasaki
authors.forename: Jun
authors.initials: J
authors.lastname: Fujikawa
authors.forename: Yukiko
authors.initials: Y
authors.lastname: Kawasaki
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Hamamoto
authors.forename: Sachiko
authors.initials: S
authors.lastname: Honjo
authors.forename: Eiko
authors.initials: E
authors.lastname: Moriishi
authors.forename: Yasuko
authors.initials: Y
authors.lastname: Mori
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Koshiyama
mesh_terms: D000368:Aged; D000914:Antibodies, Viral / Q000097:blood; D003920:Diabetes Mellitus / Q000097:blood / Q000276:immunology*; D058501:Enzyme-Linked Immunospot Assay; D005260:Female; D006386:Hemagglutination Tests; D006562:Herpes Zoster / Q000517:prevention & control; D053061:Herpes Zoster Vaccine / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology; D006801:Humans; D007111:Immunity, Cellular / Q000276:immunology; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D012882:Skin Tests
chemical_list: D000914:Antibodies, Viral; D053061:Herpes Zoster Vaccine
keywords: Cell-mediated immunity (CMI); Diabetes mellitus; Herpes zoster; Immunogenicity; Live Oka varicella vaccine; Safety